" Thyroid stunning" from diagnostic iodine-131 imaging prior to ablative therapy with 131 I for
well-differentiated thyroid carcinoma has been well reported, but documentation of the effect …

PURPOSE: To determine if stunning can be seen with a 185-MBq (5-mCi) dose of iodine
131 (131I) at diagnostic whole-body scanning and, if stunning is seen, determine if there is …

Background In the management of patients with differentiated thyroid carcinoma, direct
comparison of the presence of scintigraphic stunning after a diagnostic dose of 131 I with …

In patients with thyroid carcinoma, remnant thyroid tissue or metastases may have lower
131I uptake on posttherapy images than on prior diagnostic images. This observation has …

Detection of residual tissue after thyroidectomy for papillary or follicular thyroid carcinoma
may be performed using diagnostic imaging with either 123I or 131I. The former is often …

MATERIALS AND METHODS This retrospective study consisted of 122 consecutive patients
with well-differentiated thyroid carcinoma who were referred to our department between …

The use of 131I in doses of several mCi for scans can stun the thyrocytes and thyroid cancer
cells, whereas the usual dose (300 μCi) of 123I does not. We compared the diagnostic …

Thyroid stunning is usually defined as decreased uptake or trapping of radioiodine 131I by
normal thyroid tissue or differentiated thyroid cancer after diagnostic administration of 131I …

Radio-iodine therapy for thyroid carcinoma has been given for many years but its use
remains surrounded with controversies. Should patients routinely have thyroid remnants …

When thyroid tissues exhibited concentrations of therapeutic 131I that appeared to be less
than that predicted by data from the preceding diagnostic 131I, the phenomenon was called …